Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 3/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469916 | 1.00 | MCOLN3 (0.55) | MCOLN3PKMACHECA1CA2 | |
| SCHEMBL31536845 | 0.85 | KMT2A (0.60) | PKMACHECA1CA2CA9 | |
| SCHEMBL5188196 | 0.85 | KMT2A (0.60) | PKMACHECA1CA2CA9 | |
| SCHEMBL12888826 | 0.82 | MCOLN3 (0.57) | MCOLN3PKMACHECA1CA2 | |
| SCHEMBL533956 | 0.81 | TRPV4 (0.68) | MCOLN3PKMACHECA1CA2 | |
| SCHEMBL6367227 | 0.81 | MCOLN3 (0.55) | MCOLN3PKMACHEMEP1BALPL | |
| SCHEMBL1804739 | 0.81 | PKM (0.55) | MCOLN3PKMCA1CA2CA9 | |
| SCHEMBL2183386 | 0.81 | PKM (0.55) | PKMACHECA1CA2CA9 | |
| SCHEMBL13290903 | 0.81 | MCOLN3 (0.55) | MCOLN3PKMACHECA1CA2 | |
| SCHEMBL29551296 | 0.81 | PKM (0.55) | PKMACHECA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| CN-111362857-B | Compound with indoline skeleton, preparation method and medical application thereof | 中国药科大学 | 2023-02-28 | — | — | CN | claimed |
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-22 | — | — | US | disclosed |
| US-12053459-B2 | CDK2 inhibitors and methods of using the same | CEDILLA THERAPEUTICS, INC. (MA) | 2024-08-06 | — | — | US | disclosed |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | disclosed |
| EP-4358954-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117561058-A | CDK2 inhibitors and methods of use thereof | 塞迪拉治疗股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4229048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-6384070-B2 | RESTENOSIS, KIDNEY DISEASES, LUNG DISEASES | PFIZER INC. | 2002-05-07 | — | — | US | disclosed |
| US-6306852-B1 | INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF A VARIETY OF DISEASES INCLUDING RESTENOSIS, RENAL FAILURE AND PULMONARY HYPERTENSION, AND TO PHARMACEUTICAL FORMULATIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-20010014677-A1 | Restenosis, kidney diseases, lung diseases | RAWSON DAVID JAMES (GB) | 2001-08-16 | — | — | US | disclosed |
| US-6211223-B1 | BENZODIOXOL-5-YL-2-METHOXY-4-METHYLPHENYLSULFONYLAMINO-2-OXO ETHYL-1-METHYL-1HINDOLE-6-CARBOXYLIC ACID | PFIZER INC. | 2001-04-03 | — | — | US | disclosed |
| US-6136843-A | CARDIOVASCULAR DISORDERS; KIDNEY DISORDERS | PFIZER INC (US) | 2000-10-24 | — | — | US | disclosed |
| US-6017945-A | USEFUL IN THE TREATMENT OF RESTENOSIS, RENAL FAILURE AND PULMONARY HYPERTENSION | PFIZER INC. (US) | 2000-01-25 | — | — | US | disclosed |
| WO-1999020623-A1 | INDOLE DERIVATIVE USEFUL AS ENDOTHELIN RECEPTOR ANTAGONIST | PFIZER LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| EP-0901470-A1 | INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997043260-A1 | INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014677-A1 | Restenosis, kidney diseases, lung diseases | NR1H2, NR1H3, NR1H4 | MCOLN3 918/4885PKM 2679/4885ACHE 4882/4885 |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3R5 | MCOLN3 4258/4885PKM 3312/4885ACHE 3610/4885 |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | MCOLN3 4039/4885PKM 1158/4885ACHE 3485/4885 |
| US-12053459-B2 | CDK2 inhibitors and methods of using the same | CDK2, CDK20, CDK2AP2 | MCOLN3 4039/4885PKM 1158/4885ACHE 3485/4885 |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | MCOLN3 3052/4885PKM 2477/4885ACHE 1538/4885 |
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SULT2A1, KAT8, TST | MCOLN3 3291/4885PKM 613/4885ACHE 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.